Form 4: Metagenomi CFO Pamela Wapnick Receives Stock Options and Restricted Stock Units

Pamela Wapnick, CFO of Metagenomi, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• Pamela Wapnick, the Chief Financial Officer of Metagenomi, Inc., reported a transaction on April 1, 2024.
• Wapnick acquired 69,316 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.00.
• 25% of these RSUs will vest on September 5, 2024, with the remaining portion vesting in 12 equal quarterly installments, contingent upon continued service with the company.
• Additionally, Wapnick acquired options to buy 291,450 shares of common stock at an exercise price of $10.82.
• 25% of these options will vest on September 18, 2024, with the remainder vesting in 36 equal monthly installments, also contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as aligning management interests with shareholders.

Positives

• The grant of RSUs and stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedules incentivize continued service with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives. The vesting schedules are typical for incentivizing long-term performance.

Comparison to Industry Standards

• Equity grants to CFOs in biotech are common, with vesting schedules typically ranging from 3 to 4 years.
• The specific amounts and terms would need to be compared to peer companies of similar size and stage of development to assess competitiveness.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term value creation.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates